Taxol and Osteonecrosis of jaw - a phase IV clinical study of FDA data

Summary:

Osteonecrosis of jaw is reported as a side effect among people who take Taxol (paclitaxel), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Osteonecrosis of jaw when taking Taxol. It is created by eHealthMe based on reports of 33,313 people who have side effects when taking Taxol from the FDA, and is updated regularly.

What is Taxol?

Taxol has active ingredients of paclitaxel. It is often used in breast cancer. eHealthMe is studying from 33,554 Taxol users. Check the latest studies of Taxol.

What is Osteonecrosis of jaw?

Osteonecrosis of jaw (death of bone of jaw) is found to be associated with 1,360 drugs and 1,012 conditions by eHealthMe. Check the latest studies of Osteonecrosis of jaw.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

33,313 people reported to have side effects when taking Taxol.
Among them, 825 people (2.48%) have Osteonecrosis of jaw.

Among these 825 people:

* Approximation only. Some reports may have incomplete information.

Do you take Taxol and have Osteonecrosis of jaw?

- Check whether Osteonecrosis of jaw is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Taxol:

Taxol (33,554 reports)

Osteonecrosis of jaw treatments and more:

Osteonecrosis of jaw (36,612 reports)

How severe was Osteonecrosis of jaw and when was it recovered:

Osteonecrosis of jaw in Taxol

Expand to all the drugs that have ingredients of paclitaxel:

Osteonecrosis of jaw and drugs with ingredients of paclitaxel (1,408 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Taxol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteonecrosis of jaw:

Osteonecrosis of jaw (1,360 drugs)

Browse all the conditions that are associated with Osteonecrosis of jaw:

Osteonecrosis of jaw (1,012 conditions)

Related publications that referenced our studies

Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
Henien M, Carey B, Hullah E, Sproat C, Patel V, "methotrexate-associated osteonecrosis of the jaw: A report of two cases", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017 Dec .
Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
Henien M, Carey B, Hullah E, Sproat C, Patel V, "methotrexate-associated osteonecrosis of the jaw: A report of two cases", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on paclitaxel (the active ingredients of Taxol) and Taxol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.